16
Participants
Start Date
October 19, 2023
Primary Completion Date
January 2, 2024
Study Completion Date
January 2, 2024
zongertinib
Participants received a single oral dose of 240 mg Zongertinib (4 x 60 mg tablets) in two periods: in Period 1 after an overnight fast of at least 10 hours, and in Period 2 following a high fat/high calorie meal.
CRS Clinical Research Services Berlin GmbH, Berlin
Lead Sponsor
Boehringer Ingelheim
INDUSTRY